These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

838 related items for PubMed ID: 18175558

  • 1. [Role of serotonin in the pathophysiology of the irritable bowel syndrome].
    Moskwa A, Boznańska P.
    Wiad Lek; 2007; 60(7-8):371-6. PubMed ID: 18175558
    [Abstract] [Full Text] [Related]

  • 2. Review article: serotonin receptors and transporters -- roles in normal and abnormal gastrointestinal motility.
    Gershon MD.
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():3-14. PubMed ID: 15521849
    [Abstract] [Full Text] [Related]

  • 3. [Recent insights into the pathogenesis of abdominal symptoms in functional bowel disorders].
    Cervio E, Rondanelli M, Balestra B, Dellabianca A, Agazzi A, Giacosa A, Tonini M.
    Recenti Prog Med; 2007 Feb; 98(2):69-73. PubMed ID: 17439064
    [Abstract] [Full Text] [Related]

  • 4. Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease.
    Spiller R.
    Neurogastroenterol Motil; 2007 Aug; 19 Suppl 2():25-31. PubMed ID: 17620085
    [Abstract] [Full Text] [Related]

  • 5. Drug therapy options for patients with irritable bowel syndrome.
    Talley NJ.
    Am J Manag Care; 2001 Jul; 7(8 Suppl):S261-7. PubMed ID: 11474911
    [Abstract] [Full Text] [Related]

  • 6. Tegaserod and other serotonergic agents: what is the evidence?
    Chey WD.
    Rev Gastroenterol Disord; 2003 Jul; 3 Suppl 2():S35-40. PubMed ID: 12776001
    [Abstract] [Full Text] [Related]

  • 7. Trypsinogen IV, serotonin transporter transcript levels and serotonin content are increased in small intestine of irritable bowel syndrome patients.
    Kerckhoffs AP, Ter Linde JJ, Akkermans LM, Samsom M.
    Neurogastroenterol Motil; 2008 Aug; 20(8):900-7. PubMed ID: 18363639
    [Abstract] [Full Text] [Related]

  • 8. Drugs acting on serotonin receptors for the treatment of functional GI disorders.
    Tonini M, Pace F.
    Dig Dis; 2006 Aug; 24(1-2):59-69. PubMed ID: 16699264
    [Abstract] [Full Text] [Related]

  • 9. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome.
    Buhner S, Li Q, Vignali S, Barbara G, De Giorgio R, Stanghellini V, Cremon C, Zeller F, Langer R, Daniel H, Michel K, Schemann M.
    Gastroenterology; 2009 Oct; 137(4):1425-34. PubMed ID: 19596012
    [Abstract] [Full Text] [Related]

  • 10. Irritable bowel syndrome: new pharmaceutical approaches to treatment.
    Farthing MJ.
    Baillieres Best Pract Res Clin Gastroenterol; 1999 Oct; 13(3):461-71. PubMed ID: 10580922
    [Abstract] [Full Text] [Related]

  • 11. Tegaserod for constipation-predominant irritable bowel syndrome.
    Kale-Pradhan PB, Wilhelm SM.
    Pharmacotherapy; 2007 Feb; 27(2):267-77. PubMed ID: 17253916
    [Abstract] [Full Text] [Related]

  • 12. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.
    De Ponti F, Tonini M.
    Drugs; 2001 Feb; 61(3):317-32. PubMed ID: 11293643
    [Abstract] [Full Text] [Related]

  • 13. Expression and role of 5-HT7 receptor in brain and intestine in rats with irritable bowel syndrome.
    Zou BC, Dong L, Wang Y, Wang SH, Cao MB.
    Chin Med J (Engl); 2007 Dec 05; 120(23):2069-74. PubMed ID: 18167178
    [Abstract] [Full Text] [Related]

  • 14. Enterochromaffin cells and 5-HT signaling in the pathophysiology of disorders of gastrointestinal function.
    Crowell MD, Shetzline MA, Moses PL, Mawe GM, Talley NJ.
    Curr Opin Investig Drugs; 2004 Jan 05; 5(1):55-60. PubMed ID: 14983974
    [Abstract] [Full Text] [Related]

  • 15. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome.
    Cremon C, Carini G, Wang B, Vasina V, Cogliandro RF, De Giorgio R, Stanghellini V, Grundy D, Tonini M, De Ponti F, Corinaldesi R, Barbara G.
    Am J Gastroenterol; 2011 Jul 05; 106(7):1290-8. PubMed ID: 21427712
    [Abstract] [Full Text] [Related]

  • 16. Comparison between partial agonist (ME3412) and antagonist (alosetron) of 5-hydroxytryptamine 3 receptor on gastrointestinal function.
    Kawano K, Mori T, Fu L, Ito T, Niisato T, Yoshida S, Shiokawa S, Sato Y, Murakami H, Shishikura T.
    Neurogastroenterol Motil; 2005 Apr 05; 17(2):290-301. PubMed ID: 15787949
    [Abstract] [Full Text] [Related]

  • 17. Visceral hypersensitivity in irritable bowel syndrome.
    Kanazawa M, Hongo M, Fukudo S.
    J Gastroenterol Hepatol; 2011 Apr 05; 26 Suppl 3():119-21. PubMed ID: 21443723
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
    Rahimi R, Nikfar S, Abdollahi M.
    Clin Ther; 2008 May 05; 30(5):884-901. PubMed ID: 18555935
    [Abstract] [Full Text] [Related]

  • 19. Serotonin and its role in colonic function and in gastrointestinal disorders.
    Costedio MM, Hyman N, Mawe GM.
    Dis Colon Rectum; 2007 Mar 05; 50(3):376-88. PubMed ID: 17195902
    [Abstract] [Full Text] [Related]

  • 20. Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron.
    Bellini M, Rappelli L, Blandizzi C, Costa F, Stasi C, Colucci R, Giannaccini G, Marazziti D, Betti L, Baroni S, Mumolo MG, Marchi S, Del Tacca M.
    Am J Gastroenterol; 2003 Dec 05; 98(12):2705-11. PubMed ID: 14687821
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.